| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/01/2023 | 485.94% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 04/24/2023 | 485.94% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 04/05/2023 | 485.94% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 02/24/2023 | 485.94% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 05/02/2022 | 485.94% | HC Wainwright & Co. | $33 → $15 | Maintains | Buy |
| 01/09/2020 | 681.25% | HC Wainwright & Co. | → $20 | Initiates Coverage On | → Buy |
What is the target price for Enlivex Therapeutics (ENLV)?
The latest price target for Enlivex Therapeutics (NASDAQ: ENLV) was reported by HC Wainwright & Co. on August 1, 2023. The analyst firm set a price target for $15.00 expecting ENLV to rise to within 12 months (a possible 485.94% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Enlivex Therapeutics (ENLV)?
The latest analyst rating for Enlivex Therapeutics (NASDAQ: ENLV) was provided by HC Wainwright & Co., and Enlivex Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Enlivex Therapeutics (ENLV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enlivex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enlivex Therapeutics was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.
Is the Analyst Rating Enlivex Therapeutics (ENLV) correct?
While ratings are subjective and will change, the latest Enlivex Therapeutics (ENLV) rating was a reiterated with a price target of $0.00 to $15.00. The current price Enlivex Therapeutics (ENLV) is trading at is $2.56, which is within the analyst's predicted range.